NRAS and melanoma: In the noncutaneous melanoma cohort, the median PFS were 3.6 months (95% CI: 0.9-6.3) for NRAS mutant patients and 4.3 months (95%CI: 2.9-5.7) for wild-type patients (P=0.015), respectively, and the median OS were 10.8 months (95% CI: 1.5-20.1) and 15.3 months (95% CI: 13.2-17.4), respectively (P=0.025).